Dual blockade of the renin-angiotensin system in diabetic nephropathy

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1278-1282

  Wade, Vicki L ^a   Gleason, Brenda L ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Dual blockade; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; VALSARTAN;

BLOOD PRESSURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 3042645513     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D598     Document Type: Review

References (19)

1. American Diabetes Association. Clinical practice guidelines 2003. Diabetes Care 2003;26:S1-156.
2. Johnson JA, Parker RB, Patterson JH. Heart failure. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill, 2002:185-218.
3. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003;91(suppl): 28G-34G.
4. Diabetic nephropathy. www.nephrologychannel.com/diabeticnephropathy/ index.shtml (accessed 2003 Dec 1).
5. UK Prospective Diabetes Study Group. Tight BP control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
6. Stratton IM, Adler A, Neil AW, Matthew DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
8. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
9. Nussberger J, Brunner DB, Waeber B, Brunner HR. Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens Suppl 1985;3(suppl 3):S269-70.
10. Sica DA, Elliott WJ. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice. J Clin Hypertens 2001;3:383-7.
11. Balcells E, Meng QC, Johnson WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273(4 pt 2):H1769-74.
12. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
13. Rossing K, Hensen BR, Christensen PK, Parving H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
14. Jacobsen P, Andersen S, Jensen BR, Parving H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-9.
15. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80.
16. Rossing K, Jacobsen P, Pietraszek L, Parving H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.
17. American Diabetes Association. Diabetes and nephropathy (kidney complications). www.diabetes.org/diabetes-statistics/kidney-disease.jsp. (accessed 2004 May 5).
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
19. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-41.